ShiY, ChenG, WangX, et al.. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicenter, double-blind, randomized phase 3 study. Lancet Respir Med. 2022; 10(11):1019–1028.
2.
CooperAJ, SequistLV, LinJJ. Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management. Nat Rev Clin Oncol. 2022; 19(8):499–514.
3.
ChenCB, WuMY, NgCY, et al.Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018; 10:1259–1273.
4.
SatoI, MizunoH, KataokaN, et al.Osimertinib-Associated toxic epidermal necrolysis in a lung cancer patient harboring an egfr mutation-a case report and a review of the literature. Medicina (Kaunas)., 2020; 56(8).
